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ed.2012.Abstract This article addresses the commonly asked question––Can clinicians––be effective
researchers?
The author draws on historical discoveries by inquisitive physicians and his own experience which
involved extensive clinical research in various aspects of pulmonary medicine in USA and his more
recent experience of overseeing the development of research at King Fahd Medical City in Riyadh,
a major tertiary care center in Saudi Arabia. From this experience the author draws some conclu-
sions as to the key ingredients required for successful research, which include––the inquisitiveness,
patience, perseverance on the part of the clinician––along with a nurturing and supportive environ-
ment, with appropriate institutional ﬁnancial, emotional and administrative support. The impor-
tance of collaboration and ﬁnally the need for appropriate data collection and following the
Belmont principles need to be emphasized.
The author strongly believes that the answer to the question: Can Clinicians be effective research-
ers is a most deﬁnitive yes.
ª 2012 Taibah University. Production and hosting by Elsevier Ltd. All rights reserved.Introduction
In 2006, I was asked to help develop the research program
at King Fahd Medical City (KFMC), a new tertiary care
hospital in Riyadh consisting of four hospitals––general,
rehabilitation, women’s, children’s and staffed by profession-
als from all parts of the world. As I began to establish the
institutional review board and plant the seeds for a research
enterprise, questions were asked such as––why bother devel-ork at Stony Brook, Master
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08.002op research in a clinically oriented hospital devoted to pa-
tient care, we are clinically oriented and do not have the
expertise or know how in doing meaningful research, we
do not have the time, we already have a job, why bother
and what difference does it make anyway and ﬁnally, I
am overworked and unless I have more staff I am unable
to do ‘‘research’’.
As I began to ponder on the strategy to develop and answer
some of these real concerns I reﬂected on my own experience in
USA, where after basic training in Kashmir with no experience
in research I ended up, unplanned I might add, doing a fair
amount of clinical researchwhich over a period of twodecades re-
sulted in substantial grants and publications with some original
observations as well. I reﬂected on the studies which resulted in
grants from National Institute of Health, World Health Organi-
zation, Queens County Lung Association, Pharmaceutical Spon-
sors which approximated. 2.5 million USD=>8 million SR, in
addition as chair of medicine with the help of colleagues weLtd. All rights reserved.
2 F.A. Khanreceived substantial grants for the NewYork State Primary Care
Upweighting, HIV/AIDS Designated Center approximately:
4 million dollars =>14 million SR.
As I shared my experience with the interested staff at
KFMC slowly the interest started to blossom and one of the
most popular presentations I made at KFMC and other insti-
tutions was––Clinicians as effective researchers. In this article I
will brieﬂy outline the key ingredients which make a successful
clinical researcher, and heavily rely on my personal experience.
It goes without saying that one needs a supportive environ-
ment within the institution and also a country which under-
stands and invests in research and development with the
anticipation of long term returns.
The institutional and national priorities will not be ad-
dressed in this article.
Individulas role
Curiosity
The key element needed is a person who is curious, not afraid
to ask questions, to ‘‘think outside the box’’ and willing to fol-
low through and take chances. Few historical examples will
illuminate this point:
1929-Werner Forsmann-25 year old intern in Germany had
been deeply impressed by a sketch in his physiology textbook
that showed French physiologists standing in front of a
horse, holding a thin tube that had been put into the jugular
vein in the animals neck and then guided into one of the heart
chambers. He could not understand why this simple tech-
nique, which would avoid the complications of opening the
chest, had not already been tried on humans. Forsmann
requested permission from his boss Dr. Richard Schneider
to try this procedure on a terminally ill patient, it was ﬂatly
refused and Schneider forbade Forsmann to do the experi-
ment at all on any person, including himself.
Forsmann decided to do the experiment anyway––in secret.
With the help of nurse Gerda Ditzen, Forsmann success-
fully passed a ureteral tube through a large antecubital vein
into the right atrium and conﬁrmed this historical success
with a chest X-ray. Thus began the era of intravascular
catheterization––a procedure now taken for granted. It
was Werner Forsmann’s curiosity, persistence and willing-
ness to experiment on himself which resulted in the advent
of intravascular catheterization for which he received the
Nobel Prize in Medicine in 1956.1
1959-Victor Herbert (VH) was a 32 year old hematologist
in training in Boston, Massachusetts who believed that die-
tary deﬁciency alone can result in severe anemia which was
new thinking during Victor Herbert’s time. Sometimes,
experience with a single patient can change a researchers
thinking and that was the case with Victor Herbert when
he saw a retired engineer, who had a combination of scurvy
and folate-deﬁcient megaloblastic anemia. Herbert learned
that his patient who was on a very tight budget, ate all
his meals at a chain of fast-food hamburger stands in
Boston. As VH states: ‘‘After a diet of 15c hamburgers,
donuts and coffee for 5 years, my patient developed scurvy
and megaloblastic anemia, which I believed was due to
folate deﬁciency’’:To prove his hypothesis VH went on a strict vitamin deﬁ-
cient diet and after 133 days of Folate deﬁcient diet, weight
loss of 26 lbs, drop of hematocrit from 48 to 42, nine bone
marrow examinations exams, Victor Herbert developed
megaloblastic anemia conﬁrming cause and effect.2
Fairy tooth
Songtao Shi (SS) father of 6 years old Julia observed red tissue
inside the deciduous tooth of his daughter. From these and
other teeth SS developed SHED: Stem Cells from Human
Exfoliated Deciduous Teeth at the National Institutes of
Health laboratories. These cells have potential to develop den-
tin which one day may be used to repair damaged teeth, induce
regrowth of bone and treat nerve injury or disease, this work is
currently in progress.3
The story of stomach ulcers – acid or bacteria?
As a student in Kashmir I was taught that acid in the stomach is
the cause of the very prevalent stomach ulcers in Kashmir. We
would evenprovidemilk via nasogastric tubes forhospitalizedpa-
tientswith stomachulcers, the rationale being that themilkwould
neutralize the acid which was supposed to be the cause of the
ulceration. All this changed thirty years ago with the discovery
of Helicobacter Pylori in the stomachs of patients with gastritis
and stomach ulcers by Barry J. Marshall and J. Robin Warren
of Perth, Western Australia. At the time (1982/83) the conven-
tional thinkingwas that no bacterium can live in the human stom-
ach as the stomach produced extensive amounts of acid.
The bacterium had been observed in 1979 by Australian
pathologist Robin Warren, who did further research on it with
Australian physician Barry Marshall beginning in 1981. After
numerous unsuccessful attempts at culturing the bacteria from
the stomach, they ﬁnally succeeded in visualizing colonies in
1982 when they unintentionally left their Petri dishes incubat-
ing for 5 days over the Easter weekend. In their original paper,
Warren and Marshall contended that most stomach ulcers and
gastritis were caused by infection by this bacterium and not by
stress or spicy food as had been assumed before.4
To demonstrate that H. pylori caused gastritis and was not
merely a bystander, Marshall drank a beaker of H. pylori. He
became ill several days later with nausea and vomiting. An
endoscopy ten days after inoculation revealed signs of gastritis
and the presence of H. pylori. These results suggested that H.
pyloriwas the causative agent of gastritis. Marshall andWarren
went on to show that antibiotics are effective in the treatment of
many cases of gastritis. Warren andMarshall were awarded the
Nobel Prize in Medicine in 2005 for their work on H. pylori.
There are numerous other similar observations which have
resulted in major discoveries and the book Who Goes First by
Altman summarizes many of these facts.1,2
What is research?
Often I get asked this question, the ‘common’ perception of
research is doing some experimental work in a laboratory,
a more appropriate deﬁnition of research is careful investiga-
tion into some subject––hypothesis––or area of study with the
aim of discovery and applying new facts or information, in
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ter patient care, the examples I cited above are classic cases
of research which ﬁt this deﬁnition, one could expand the
scope and do research and try to seek answers for questions
like, why people smoke knowing fully that its harmful, why is
obesity becoming so prevalent particularly in some ethnic
groups, in Saudi Arabia road trafﬁc accidents are common,
why do Saudi’s drive the way they do, when someone has
a stroke what is the outcome particularly regarding quality
of life, why some centers have better outcomes than others,
what is the most effective way of delivery of health care,
why is that in spite of spending the largest amount of money
on health care in USA, the country does not have the best
outcomes in objective parameters of health delivery. These
are all areas of great interest awaiting clinicians research––
posing the question and then studying the problem in a sys-
tematic organized manner, with the ultimate goal of improv-
ing patient care.
Two examples from personal experience
Data collection
After completing my training in medicine/pulmonary I worked
in a newly initiated respiratory intensive care unit in Queens
General hospital (QGH) in New York. It became apparent very
quickly that a signiﬁcant number of the patients admitted and
intubated for Respiratory failure were developing complica-
tions manifesting as massive gastro intestinal bleeding, renal
failure, nosocomial infections, tracheal complications from
endotracheal tubes and tracheostomies. To develop some data
regarding the incidence, causes and impact on morbidity and
mortality, with the help of the cooperative nursing staff, I ‘‘in-
vested’’ in a notebook which cost me 85 cents––approximately
three Riyals. In this notebook the nursing staff recorded all
admissions and marked any complications that developed. At
the end of the month I would look over these data and analyze
the months admission of 25–30 patients, I noticed fewGI bleed-
ers and few with other complications, over a period of several
months we had data on a hundred plus patients and during
my stay at QGH from 1972 to 1986 I accumulated data on over
three thousand patients. Aside from the data entry by the nurses
all the remaining work was done by me––there was no protected
time in a busy public hospital. We had an incidence of over ten
percent patients with massive GI bleeding––requiring two or
more units of blood transfusion––to reduce the incidence we
adopted gastric neutralization program initially with antacids
and later onH2 blockers with dramatic improvement in the inci-
dence and reported the largest series on this subject5 We had
similar experience in addressing complications of renal failure,
tracheal complications and after presenting our ﬁndings at na-
tional meetings we were asked to write a monograph on the
subject.6 Take home message from this experience is that you
need to have accurate reliable transparent data and from such
accumulated experience one can make interesting observations
which often lead to better patient care.
Patience and collaboration
In mid eighties I served as external examiner for the medical
school in Amman, one of the ‘‘short’’ cases presented was thatof a Palestinian teenager with classic saccular bronchiectasis.
The diagnosis was obvious and the students had no difﬁculty
in describing the clinical ﬁndings. However, later that evening
Prof. Naif Sliman posed the following question: ‘‘The case of
Bronchiectasis you saw today is rather unusual in that he
and several of his brothers have the same problem and they
are challenged intellectually, the sisters and other siblings do
not have this problem, can you help us sort this out?’’ It was
clear that there was some inherited genetic disorder affecting
some but not all male siblings in this rather large Palestinian
family of fourteen plus siblings. We went through the usual
differential diagnosis, did the chromosome analysis, studied
the cilia from the affected patients and other routine investiga-
tions. The affected family was living in a refugee camp in
Jordan and I was in New York and this created many interest-
ing challenges in the logistics of obtaining samples, transport-
ing them from Amman to USA. We had to seek the assistance
of experts from diverse ﬁelds involving genetics, ciliary sam-
pling and motility studies. After ﬁfteen years of collaboration
and work with many investigators in––Amman-Jordan, Atlan-
ta, (GA), Stony Brook, (NY), and Charleston, (SC) in United
States of America, we were able to identify a new inherited ge-
netic disease.7 The lessons learnt from this experience is that
investigation and research can take a long time, one needs to
be patient and most importantly one needs to collaborate with
the appropriate investigators within and outside the parent
institution. This ‘‘research’’ took 15 years.
Ethics in research
After serving on the board of the professional medical conduct
in New York it became apparent to me that physicians are not
immune from ethical lapses, this becomes even more important
in research where patients are entrusting the physicians to
being subjected to an unproven, often not approved medica-
tion or device. Two personal examples will highlight this.
(A) I did sizable clinical research in the ﬁeld of applications
of ﬂuroquinolones in respiratory tract infections,8 as our
team published and presented our ﬁndings in profes-
sional meetings I began to receive requests from several
different pharmaceutical companies to test their prod-
uct. One such product had obvious frequent neurologic
complications, every third or fourth enrolled patient had
some evidence of neurologic stimulation––irritability,
sleeplessness and even seizures. I felt exposing my
patients to such side effects was not appropriate and
quickly informed my IRB that I was cancelling the
study.
(B) While studying Ciproﬂoxacin which had been showing
excellent clinical results, one of our enrolled patients
had a grand mall seizure which she never had before,
after careful clinical investigation we determined it was
most likely the result of a very high blood theophylline
level, up to that time Ciproﬂoxacin had not been known
to increase the blood theophylline level. The sponsoring
company was quickly advised of this complication and
to their credit they encouraged us to study this interac-
tion in greater detail, which we did and thus established
the Ciproﬂoxacin-Theophylline interaction.9 The point
in these two examples is that complications can occur
while doing research, it’s the investigators responsibility
4 F.A. Khanand moral/ethical duty to weigh the risk/beneﬁt ratio
carefully keeping the patients interest and well being
uppermost in mind.
A study of the experience of a well respected researcher at
NIH when he encountered several deaths in patients he was
treating with an investigational drug is highly recommended
for all who do clinical research.10
In the developing world there are additional barriers which
create challenges for a budding young clinician which have
been summarized in a recent publication.11
Financial support for research
Developed countries have recognized the fact that support for
research and development pays rich dividends in the long run,
the amount invested in research and development varies
widely––Japan with 2.9% of the gross domestic product(GDP)
for research, in Europe it averages between 1.5% and 3% of
the GDP, The South East Asian countries average 0.89%
GDP and in the Arab countries it averages 0.23% of the
GDP, with the exception of Qatar with 2.8%. These numbers
translate to $ 19 per person in Saudi Arabia, $ 665 per person
in USA and $ 649 per person in Japan. During my stay in the
kingdom of Saudi Arabia I noticed increasing emphasis and
support for research, however my attempts to obtain accurate
information regarding national allocation of funds for medical
research in the kingdom were not successful.
A good example of the rich returns for research investment
are evident with the recent epidemic of HIV/AIDS, which in
the mid eighties had no treatment and had a very high fatality
rate, if this trend had continued it is estimated we would have
over––200,000 hospital beds occupied by AIDS patients.
Thankfully, with an investment of ten billion dollars over ten
years the virus was identiﬁed, drugs were discovered and the
fatal infection changed from an inpatient hospital service to
an outpatient long term care illness. Thus the 10 billion invest-
ment saved 1.4 trillion in health care costs or a return of S140
for every dollar spent.12
Conclusion
Based on my personal experience as a clinical researcher and
having overseen the expanding research at KFMC since 2006
the key ingredients for success are: intellectual curiosity, asking
the key question – , ‘‘But Why’’, persistence and follow up to
test your hypothesis, honesty and integrity in collecting and
reporting all ﬁndings both the expected and the unexpected,
assess what’s available and doable in the place you work ex
there is no point doing research in transplantation if your
institution does not have a transplant program, learn to collab-
orate and co-operate, locally, nationally and even internation-
ally, this is particularly important in developing countries such
as Saudi Arabia. Clinicians can start from simple research,
gain knowledge, experience and conﬁdence and then embark
on funded projects.
There is an element of luck involved, being in the right envi-
ronment, having access to role models, cooperative peers is
important.Finally I cannot stress strongly enough the importance of
data collected on––Index Cards-Notebook, Palm pilots––Cor-
tex, just collect data, analyze your results and ideas usually
ﬂow from the accumulated data. It is important for the re-
searcher to realize that unless the results of the research are
published, they are of much less value for the larger commu-
nity. With the modern tools of communication, publishing of
results has become lot less complicated compared to the time
before the advent of internet and computers. Picking the right
journal and getting the material published is a subject for an-
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